Nanobodies reveal the interaction between mGlu2 and TrkB and improve the mechanism of schizophrenia
Current schizophrenia drugs mainly block dopamine D2 and 5‑HT receptors, relieving positive symptoms but not negative ones. mGlu2, a GPCR that regulates glutamate transmission, may improve both positive and cognitive symptoms. However, multiple mGlu2‑targeted drugs, including Eli Lilly’s mGlu2/3 agonist pomaglumetad, failed in clinical trials, suggesting a key gap in mechanistic understanding.
Read More...